This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cacciapuoti, A.
Right arrow Articles by Loebenberg, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cacciapuoti, A.
Right arrow Articles by Loebenberg, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2006, p. 2587-2590, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00829-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Interaction between Posaconazole and Caspofungin in Concomitant Treatment of Mice with Systemic Aspergillus Infection

Anthony Cacciapuoti,* Judith Halpern, Cara Mendrick, Christine Norris, Reena Patel, and David Loebenberg

Schering-Plough Research Institute, Kenilworth, New Jersey

Received 30 June 2005/ Returned for modification 12 October 2005/ Accepted 21 April 2006

The interaction of posaconazole and caspofungin was evaluated in concomitant treatment of Aspergillus fumigatus (two strains) or A. flavus (one strain) systemic infections in immunocompetent mice. Survival curves for mice treated with the combinations were compared statistically with those for mice treated with the component monotherapies. No antagonism was observed.


* Corresponding author. Mailing address: Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033. Phone: (908) 740-3139. Fax: (908) 740-3918. E-mail: anthony.cacciapuoti{at}spcorp.com.


Antimicrobial Agents and Chemotherapy, July 2006, p. 2587-2590, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00829-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Antachopoulos, C., Meletiadis, J., Sein, T., Roilides, E., Walsh, T. J. (2008). Comparative In Vitro Pharmacodynamics of Caspofungin, Micafungin, and Anidulafungin against Germinated and Nongerminated Aspergillus Conidia. Antimicrob. Agents Chemother. 52: 321-328 [Abstract] [Full Text]  
  • Guembe, M., Guinea, J., Pelaez, T., Torres-Narbona, M., Bouza, E. (2007). Synergistic Effect of Posaconazole and Caspofungin against Clinical Zygomycetes. Antimicrob. Agents Chemother. 51: 3457-3458 [Full Text]  
  • Antachopoulos, C., Meletiadis, J., Sein, T., Roilides, E., Walsh, T. J. (2007). Concentration-Dependent Effects of Caspofungin on the Metabolic Activity of Aspergillus Species. Antimicrob. Agents Chemother. 51: 881-887 [Abstract] [Full Text]